Vaccine approaches conferring cross-protection against influenza viruses

Abstract

Introduction Annual vaccination is one of the most efficient and cost-effective strategies to prevent and control influenza epidemics. Most of currently available influenza vaccines are strong inducer of antibody responses against viral surface proteins, hemagglutinin (HA) and neuraminidase (NA), but are poor inducers of cell-mediated immune responses against conserved internal proteins. Moreover, due to the high variability of viral surface proteins because of antigenic drift or antigenic shift, many of the currently licensed vaccines confer little or no protection against drift or shift variants. Areas covered Next generation influenza vaccines that can induce humoral immune responses to receptor-binding epitopes as well as broadly neutralizing conserved epitopes, and cell-mediated immune responses against highly conserved internal proteins would be effective against variant viruses as well as a novel pandemic influenza until circulating strain-specific vaccines become available. Here we discuss vaccine approaches that have potential to provide broad spectrum protection against influenza viruses. Expert opinion Based on current progress in defining cross-protective influenza immunity, it seems that the development of a universal influenza vaccine is feasible. It would revolutionize the strategy for influenza pandemic preparedness, and significantly impact the shelf-life and protection efficacy of seasonal influenza vaccines.

Exploring Influenza Vaccine Uptake and Its Determinants among University Students: A Cross-Sectional Study

“…Vaccination is the only established option to prevent a susceptible host from contracting influenza infection and developing its severe complications [8,9]. Immunization offers direct protection in…”

Polymorphism and selection pressure of SARS-CoV-2 vaccine and diagnostic antigens: implications for immune evasion and serologic diagnostic performance

“…It is thus of key importance to consider these aspects for serological test and vaccine development, to ensure their usefulness and broad efficacy. This is commonly done for influenza vaccines for example, that are updated each year based on circulating viral strains, as cross protection among strains is still elusive (16). We investigated here the sequence diversity of two major antigens of the novel SARS-CoV-2 virus, the N and S proteins.…”

New vaccines on the horizon

“…Upotrebom vektora, imunski odgovor se može usmeriti na određeni protein ili čak epitop, koji je antigenski konzerviran između različitih sojeva patogena, što ih čini korisnim za stvaranje univerzalnih heterosubtipskih vakcina (npr. za grip) (48). U jedan virusni genom mogu se ugraditi i geni različitih patogena, što bi obezbedilo nastanak polivalentnih vakcina (49).…”